Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies

Area of Science:

• Oncology
• Pharmaceutical Chemistry
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) are targeted cancer therapies delivering cytotoxic payloads (PLs) to tumor cells.
• Approved ADCs demonstrate clinical success, but challenges in linker stability and conjugation heterogeneity persist.
• Optimizing ADC design requires advancements in linker chemistry and conjugation technologies.

Purpose of the Study:

• To review recent advances in linker chemistry and site-specific conjugation for Antibody-drug conjugates (ADCs).
• To discuss strategies for overcoming challenges in ADC development, including linker stability and payload delivery.
• To highlight innovative conjugation technologies enhancing ADC homogeneity, stability, and therapeutic performance.

Main Methods:

• Review of recent literature on linker chemistry and conjugation technologies in ADC development.
• Discussion of traditional versus advanced conjugation methods (e.g., lysine, cysteine, site-specific).
• Analysis of novel linker components, chemical handles, spacers, and release triggers.

Main Results:

• Advances in linker chemistry, including cleavable linkers, have improved ADC clinical success.
• Site-specific conjugation technologies (e.g., THIOMAB, SMARTag, AJICAP) enhance ADC homogeneity and stability.
• New strategies address toxicity and off-target effects, improving therapeutic indices.

Conclusions:

• Linker chemistry and site-specific conjugation are critical for next-generation ADC development.
• Innovations in conjugation technologies are key to optimizing ADC efficacy and safety.
• Further research into ADC linker and conjugation strategies will advance targeted cancer therapy.